Skip to main navigation Skip to search Skip to main content

Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium

  • Loretta J. Nastoupil
  • , Michael D. Jain
  • , Lei Feng
  • , Jay Y. Spiegel
  • , Armin Ghobadi
  • , Yi Lin
  • , Saurabh Dahiya
  • , Matthew Lunning
  • , Lazaros Lekakis
  • , Patrick Reagan
  • , Olalekan Oluwole
  • , Joseph McGuirk
  • , Abhinav Deol
  • , Alison R. Sehgal
  • , Andre Goy
  • , Brian T. Hill
  • , Khoan Vu
  • , Charalambos Andreadis
  • , Javier Munoz
  • , Jason Westin
  • Julio C. Chavez, Amanda Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke
  • University of Texas MD Anderson Cancer Center
  • Moffitt Cancer Center
  • Stanford University
  • Washington University St. Louis
  • Mayo Clinic Rochester, MN
  • University of Maryland, Baltimore
  • University of Nebraska Medical Center
  • University of Miami
  • University of Rochester
  • Vanderbilt University
  • University of Kansas
  • Wayne State University
  • University of Pittsburgh
  • Cleveland Clinic Foundation
  • University of California at San Francisco
  • Banner Health

Research output: Contribution to journal › Article › peer-review

748 Scopus citations

Abstract

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication. PATIENTS AND METHODS Data were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution's guidelines. Responses were assessed as per Lugano 2014 classification. RESULTS Of 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel-treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis. CONCLUSION The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.

Original languageEnglish
Pages (from-to)3119-3128
Number of pages10
JournalJournal of Clinical Oncology
Volume38
Issue number27
DOIs
StatePublished - 20 Sep 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium'. Together they form a unique fingerprint.

Cite this